07666.HK
METIS TECHBIO-P
HKSE · Healthcare · Biotechnology · CN
HKD 11.15
−1.68%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +232.8%
- EBITDA
- -9.8%
- EBIT
- -2.0%
- Net income
- +21.6%
- EPS
- +22.0%
- Free cash flow
- +42.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025